Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.82 |
| ▸ | EGFR | P00533 | 12/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.71 |
| ▸ | FBP1 | P09467 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | PRNP | P04156 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349199 | 0.90 | MAPK1 (1.00) | MAPK1EGFRERBB2KDM4EHTT | |
| Hydrochloric Acid SCHEMBL6186081 | 0.89 | MAPK1 (0.97) | MAPK1EGFRERBB2KDM4EHTT | |
| SCHEMBL8871863 | 0.89 | EGFR (0.82) | MAPK1EGFRERBB2KDM4EHTT | |
| SCHEMBL5564480 | 0.86 | MAPK1 (0.76) | MAPK1EGFRERBB2KDM4EHTT | |
| SCHEMBL15070939 | 0.85 | EGFR (0.71) | MAPK1EGFRERBB2KDM4EABCG2 | |
| SCHEMBL1417740 | 0.85 | EGFR (1.00) | MAPK1EGFRERBB2ABCG2FBP1 | |
| SCHEMBL31060998 | 0.85 | EGFR (1.00) | MAPK1EGFRERBB2ABCG2FBP1 | |
| SCHEMBL2101381 | 0.84 | HTT (1.00) | MAPK1EGFRERBB2KDM4EHTT | |
| SCHEMBL3664557 | 0.84 | EGFR (0.81) | MAPK1EGFRERBB2ABCG2FBP1 | |
| SCHEMBL5569022 | 0.84 | HTT (0.72) | MAPK1EGFRERBB2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070258904-A1 | Optical Imaging Contrast Agents | KLAVENESS JO | 2007-11-08 | — | — | US | disclosed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258904-A1 | Optical Imaging Contrast Agents | IQGAP1, AQP3, OLA1 | MAPK1 1163/4885EGFR 157/4885ERBB2 1243/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | MAPK1 1019/4885EGFR 1445/4885ERBB2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.